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Rett syndrome (RTT) is a neurodevelopmental autism spectrum disorder that affects girls due primarily to
mutations in the gene encoding methyl-CpG binding protein 2 (MECP2). The majority of RTT patients carry
missense and nonsense mutations leading to a hypomorphic MECP2, while null mutations leading to the
complete absence of a functional protein are rare. MECP2 is an X-linked gene subject to random X-chromo-
some inactivation resulting in mosaic expression of mutant MECP2. The lack of human brain tissue motivates
the need for alternative human cellular models to study RTT. Here we report the characterization of a MECP2
mutation in a classic female RTT patient involving rearrangements that remove exons 3 and 4 creating a func-
tionally null mutation. To generate human neuron models of RTT, we isolated human induced pluripotent
stem (hiPS) cells from RTT patient ﬁbroblasts. RTT-hiPS cells retained the MECP2 mutation, are pluripotent
and fully reprogrammed, and retained an inactive X-chromosome in a nonrandom pattern. Taking advantage
of the latter characteristic, we obtained a pair of isogenic wild-type and mutant MECP2 expressing RTT-hiPS
cell lines that retained this MECP2 expression pattern upon differentiation into neurons. Phenotypic analysis
of mutant RTT-hiPS cell-derived neurons demonstrated a reduction in soma size compared with the isogenic
control RTT-hiPS cell-derived neurons from the same RTT patient. Analysis of isogenic control and mutant
hiPS cell-derived neurons represents a promising source for understanding the pathogenesis of RTT and
the role of MECP2 in human neurons.
INTRODUCTION
Rett syndrome [RTT (MIM 312750)] is a neurodevelopmental
disorder affecting roughly 1 in 10 000 live female births (1).
RTT girls develop normally until 6–18 months of age when
they enter a stage of developmental arrest. Clinical features
include microcephaly, characteristic hand wringing, autistic
features, loss of language, and mental retardation (2). Geneti-
cally, over 95% of classic RTT patients harbour a
loss-of-function mutation in an X-linked gene encoding the
methyl-CpG binding protein 2 (MECP2) (3). MECP2 func-
tions as a transcriptional regulator, both as an activator and
repressor, by binding to methylated CpG dinucleotides of
target genes via its methyl-CpG binding domain (MBD) and
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tional repression domain (TRD) (4–8).
Most mutations in MECP2 are de novo from the paternal
germline involving a C-to-T mutation at CpG hotspots
(9,10). In North America,  39 and  35% of RTT patients
are due to missense and nonsense mutations in MECP2,
respectively, while large deletions are relatively rare ( 6%)
(11–15). Furthermore, as MECP2 is X-linked, it is subject
to the effect of X-chromosome inactivation (XCI) in female
cells. XCI occurs during female development when one of
the two X-chromosomes is randomly inactivated such that
approximately half the cells inactivate the maternally
derived X-chromosome, while the other half inactivates the
paternally derived X-chromosome (16). Therefore, RTT
patients are mosaic where half of their cells express wild-type
(WT) MECP2, while the other half express mutant MECP2.
However, although XCI is random in most cases, it can
occasionally be nonrandom which could lead to phenotypic
variability in RTT patients depending on the extent of favour-
able XCI skewing (17).
Most of our understanding of RTT and MECP2 has been
attributed to the study of Mecp2 mutant mouse models as
access to patient neurons, such as postmortem tissues, is
severely limited and may not accurately reﬂect early pathogen-
esis of RTT (18). Although, Mecp2 mutant mouse models reca-
pitulate key characteristics associated with RTT patients
includinganinitialphaseofapparentlynormaldevelopmentfol-
lowed by severe neurodevelopmental dysfunction, there is evi-
dence that mouse models are an underrepresentation of the
human condition (19–21). Mecp2
2/y mice are viable, whereas
the equivalent mutation in human males is associated with
severe congenital encephalopathy and early death (22).
Disease onset in RTT mouse models is during adulthood,
whereas disease onset in RTT patients is during childhood (2).
This could be due to the fact that RTT mouse models exhibit
unbalanced XCI favouring the expression of WT Mecp2,
whereas in RTT patients, balanced XCI is the norm (23–25).
For these reasons, a method that will allow for the generation
oflargenumbersofaffectedneuronsdirectlyfromRTTpatients
will be advantageous to further understand the role of MECP2
and pathogenesis of RTT in human neurons.
Human induced pluripotent stem (hiPS) cells, which are
similar to human embryonic stem (hES) cells molecularly and
functionally, can be derived from adult somatic cell types via
the introduction of deﬁned transcription factors (26–28). The
generation of patient-speciﬁc hiPS cells has major implications
for translational medicine, such as disease phenotyping, drug
screens,andcelltherapy.Indeed,hiPScellshavebeengenerated
from a variety of diseases where speciﬁc phenotypes have been
observed in vitro and proof-of-principle drug screens have been
performed (29–37). More recently, it has been observed that
femalehiPScellsretainaninactive X-chromosomeinanonran-
dom pattern (38), in contrast to their mouse counterparts which
reactivate the inactive X-chromosome thus carrying two active
X-chromosomes and exhibit random XCI upon differentiation
(39). This pattern of XCI in female hiPS cells provide prospects
to isolate isogenic control and experimental hiPS cell lines for
heterozygous X-linked diseases, such as RTT.
Here we report the characterization of a functionally null
mutation in MECP2 attributable to rearrangements removing
exons 3 and 4 (D3–4) in a classic RTT patient. We generated
hiPS cells from this patient, predicted to carry a severe
mutation, and demonstrate that these hiPS cells are pluripotent
and fully reprogrammed. Taking advantage of the fact
that female hiPS cells retain an inactive X-chromosome in a
nonrandom pattern, we obtained hiPS cell lines with alterna-
tive parental X-chromosomes inactivated. Directed differen-
tiation of hiPS cells into neurons demonstrated that MECP2
expression follows the XCI pattern, allowing the generation
of a pair of isogenic control (expressing WT MECP2) and
experimental (expressing mutant MECP2) hiPS cell lines
which have important prospects for downstream applications.
RESULTS
Characterization of the D3–4 MECP2 mutation
The majority of RTT patients carry missense and nonsense
mutations in the MECP2 gene leading to a hypomorphic
protein with partial function, while null mutations leading to
the complete absence of a functional protein are relatively
rare (21,40,41). Preliminary screening for mutations in a
6-year-old classic RTT patient using multiplex ligation-
dependent probe ampliﬁcation indicated that she carries a del-
etion involving exons 3 and 4 of MECP2 (data not shown).
She has growth and developmental delay, inability to walk
without assistance, ataxia, nonverbal, has no hand use and
constant repetitive hand motions, some tremor, has had epi-
leptic seizures and signiﬁcant abnormal electroencephalo-
gram, teeth grinding, some sleep difﬁculties, and breath
holding and hyperventilation.
To precisely map the D3–4 MECP2 mutation of this RTT
patient, a skin punch biopsy was obtained, ﬁbroblasts expanded
and DNA harvested for genotyping. Quantitative polymerase
chain reaction (qPCR) with primers spanning the MECP2
locus was performed on D3–4-ﬁbroblasts to determine copy
number variations (Fig. 1A and B). The region of the break-
points was identiﬁed, allowing primers to be designed that
span the D3–4MECP2 mutation and amplify the mutant D3–4
MECP2 allele (Fig. 1C). Sequencing of the mutant D3–4
MECP2 allele revealed a pair of deletions, g.61340_
67032delinsAGTTGTGCCAC and g.67072_67200del, where
the larger deletion was also associated with an 11 bp insertion,
ultimately removing the entire exon 3 and the 5′ end of exon
4, including the MBD and TRD (Fig. 1A). Further analysis of
theD3–4MECP2mutationrevealedgeneticfeaturesassociated
withgenomiccopynumbervariations(SupplementaryMaterial,
Fig. S1a). We detected an AluSx element spanning the 5′ end of
the larger deletion (g.61340_67032delinsAGTTGTGCCAC)
(Supplementary Material, Fig. S1b), which could potentially
trigger Alu recombination-mediated deletions (42–44). We
were not able to determine the origin of the insertion associated
with the larger deletion as an 11 bp motif is insufﬁcient to accu-
rately perform a genome search (Supplementary Material,
Fig.S1c).However,theco-occurrenceofaninsertionwithadel-
etion has been observed previously and the insertion is thought
to originate from an inversion of the local genomic sequence
(44,45). On the other hand, we detected a 3 bp microhomology
sequence ﬂanking the smaller deletion (g.67072_67200del)
(Supplementary Material, Fig. S1d), which could potentially
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microhomology-mediated end joining or microhomology-
mediated break-induced replication (43–45). Therefore, it
appearsthatthetwodeletionsmayhavebeencausedbytwosep-
arate mechanisms. Together, these data demonstrate the identi-
ﬁcation of a complex mutation comprising a pair of deletions,
where the larger deletion is also associated with an insertion,
within the MECP2 gene, removing the two important
domains, in a classic RTT patient.
Generation and characterization of RTT-hiPS cells
The predicted severity of the D3–4 MECP2 mutation
prompted us to generate hiPS cells from this patient. D3–4-
ﬁbroblasts were transduced with OCT4, SOX2, KLF4 and
c-MYC retroviral vectors and the EOS lentiviral vector that
reports pluripotency as previously described (30,46). Three
D3–4-hiPS cell lines propagated robustly under puromycin
selection driven by the EOS-pluripotent reporter and were sub-
jected to further characterization. D3–4-hiPS cells were plur-
ipotent and fully reprogrammed as indicated by the expression
of pluripotency-associated markers, including bona ﬁde hiPS
cell markers REX1, ABCG2, DNMT3B and TRA1-60 (47)
(Fig. 2A and B, Supplementary Material, Fig. S2a). Their
ability to differentiate into the three germ layers was shown
in vitro via embryoid body formation (Fig. 2C, Supplementary
Material, Fig. S2b) and in vivo via teratoma formation by
injection into immunodeﬁcient mice (Fig. 2D, Supplementary
Material, Fig. S2c). DNA ﬁngerprinting by short tandem
repeat analysis indicated that all RTT-hiPS cells came from
their ﬁbroblast of origin and not from contaminating hES
cells within the laboratory (Fig. 2E). D3–4-hiPS cells were
fully reprogrammed, as retroviral transgenes were largely
silenced and have simultaneously reactivated the endogenous
loci of the reprogramming factors similar to previously pub-
lished patient-speciﬁc hiPS cell lines (29,31,32) (Fig. 2F).
D3–4-hiPS cells maintained a normal female karyotype
(Fig. 2G, Supplementary Material, Fig. S2d). Finally, we con-
ﬁrmed that the D3–4-hiPS cells carried the D3–4 MECP2
mutant and WT allele present in the parental ﬁbroblasts
(Fig. 1).
In addition, we acquired additional primary ﬁbroblasts from
the Coriell Cell Repository which carried a common
RTT-associated p.T158M point mutation in MECP2 for repro-
gramming. Three T158M-hiPS cell lines were generated and
were shown to be pluripotent and fully reprogrammed using
a similar panel of characterization assays and carried the
p.T158M mutation (Supplementary Material, Figs S3 and
S4). From these data, we conclude that the RTT-hiPS cells
carry a RTT-associated mutation and are pluripotent and
fully reprogrammed.
RTT-hiPS cells retain an inactive X-chromosome
in a nonrandom pattern
It has been recently demonstrated that female hiPS cells retain
an inactive X-chromosome (38). Furthermore, individual
female hiPS cell lines exhibit a nonrandom pattern of XCI
as they reﬂect the XCI status of the single ﬁbroblast from
which they were derived (38). This is advantageous for the
Figure 1. Mapping of the D3–4MECP2 mutation. (A) Schematic of the MECP2 locus. Primers used for analysis of copy number variations and their approxi-
mate amplifying regions are indicated, where applicable, with orange bars. Primers in italics belong to intron 2. Primers in dark blue were used for ampliﬁcation
of WT (KR6-Fwd and KR16-Rev) and mutant D3–4 (AC7-Fwd and KR16-Rev) MECP2 alleles in (C) and their approximate location are indicated with dark
blue arrows. The two alleles of MECP2 are indicated with red bars. There are two deletions that comprise the D3–4 MECP2 mutation, g.61340_67032delin-
sAGTTGTGCCAC and g.67072_67200del. The pair of deletions is indicated by the absence of one of the red bars indicative of the deletion of one of the two
alleles creating a heterozygous deletion. The insertion associated with the larger deletion is indicated with a light blue bar. The nomenclature of the mutations
relates to the genomic DNA sequence with position 1 deﬁned as the ﬁrst nucleotide of NG_007107.1 (NCBI: reference sequence). The approximate locationo f
the p.T158M and p.R306C mutations is indicated. MBD, methyl-CpG binding domain; TRD, transcriptional repression domain; UTR, untranslated region.( B)
qPCR analysis of copy number variations along the MECP2 locus. Data are expressed as mean+SEM. (C) PCR using WT and mutant-speciﬁc primers to
amplify the WT and D3–4 MECP2 allele, respectively.
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allows the generation of hiPS cell lines that express either
the WT or mutant form of the protein depending on the
pattern of XCI, ultimately allowing the generation of isogenic
control (expressing WT MECP2) and experimental (expres-
sing mutant MECP2) hiPS cell lines. Therefore, we sought
to determine whether RTT-hiPS cells retain an inactive
X-chromosome, and if so, whether it exhibits a nonrandom
pattern of XCI.
To investigate the XCI status of D3–4-hiPS cells, we
probed for the expression of XIST RNA, a key molecule
transcribed from the inactive X-chromosome during the
initiation of XCI (48), by RNA ﬂuorescence in situ hybridiz-
ation (RNA-FISH). We observed a single XIST RNA signal
in 67–100% of D3–4-hiPS cell colonies (Fig. 3A). We note
that of the 73% D3–4-hiPS #6 colonies where a single XIST
RNA signal was detectable, 38% of the colonies (categorized
as mix) were below the threshold for a positive colony (.90%
of cells per colony). We further assessed the XCI status of
D3–4-hiPS cells by immunocytochemistry for histone H3
lysine 27 trimethylation (H3K27me3), a repressive chromatin
mark which accumulates on the inactive X-chromosome
Figure 2. D3–4-hiPS cells are pluripotent and fully reprogrammed. (A) D3–4-hiPS #37 express pluripotency markers by immunocytochemistry. Scale bars,
100 mm. (B) D3–4-hiPS cells express bona ﬁde hiPS cell markers by qRT–PCR. Data are expressed as mean+SEM. (C) D3–4-hiPS #37 differentiate into
the three germ layers, ectoderm (TUJ1, NESTIN), mesoderm [MYOSIN, SMA (SMOOTH MUSCLE ACTIN)] and endoderm (GATA4, SOX17), in vitro
via embryoid body formation. Scale bars, 50 mm. (D) D3–4-hiPS #37 differentiates into the three germ layers, ectoderm (pigmented epithelium), mesoderm
(cartilage) and endoderm (gut epithelium), in vivo via teratoma formation by injection into immunodeﬁcient mice. Scale bars, 50 mm. (E) D3–4-hiPS cells
carry identical short tandem repeat proﬁle as their parental ﬁbroblast of origin and are distinct from CA1 hES cells in the laboratory. (F) qRT–PCR shows
that D3–4-hiPS cells have largely silenced the reprogramming vectors in comparison to IMR90-4F+RFP and have reactivated the endogenous loci of the repro-
gramming factors similar to H9 hES cells. ‘pMXs’ and ‘Endo’ refers to primers speciﬁcally recognizing the exogenous reprogramming factors and endogenous
loci, respectively. Data are expressed as mean+SEM. (G) D3–4-hiPS #37 carries a normal female karyotype by G-banding analysis.
2106 Human Molecular Genetics, 2011, Vol. 20, No. 11during the initiation of XCI (49). Similar to XIST RNA, we
observed a single H3K27me3 signal in 55–100% of the
D3–4-hiPS cell colonies (Fig. 3B). Similar results were
observed in the T158M-hiPS cells as they expressed a single
XIST RNA and H3K27me3 signal in 60–77% and 56–75%
of the hiPS cell colonies, respectively (Supplementary
Material, Fig. S5).
The accumulation of a single XIST RNA and H3K27me3
signal, combined with a skewed XCI pattern (see below), in
the RTT-hiPS cells suggests they retain an inactive X-chromo-
some. Intriguingly, in all but one RTT-hiPS cell line, variabil-
ity within colonies was not observed. The lack of a single XIST
RNA and H3K27me3 signal in some of the RTT-hiPS cells
could be interpreted as: (i) the loss of an X-chromosome
(i.e. 45, XO), (ii) the reactivation of the inactive X-chromo-
some, or (iii) an inactive X-chromosome that has lost XIST
RNA and H3K27me3 but remains transcriptionally sup-
pressed. We exclude the possibility for the loss of an
X-chromosome as D3–4-hiPS #37 possess two X-
chromosomes as observed by X-centromere DNA-FISH
(Supplementary Material, Fig. S6), consistent with a normal
female karyotype (Fig. 2G). We also exclude the possibility
that RTT-hiPS cells carry two active X-chromosomes since
neuronal derivates of RTT-hiPS cells do not exhibit random
XCI (see below). Therefore, we favour the ﬁnal possibility
as it has been previously demonstrated that female hiPS and
hES cells can be subject to the loss of XIST RNA and other
repressive chromatin marks (including H3K27me3) during in
vitro culture (38,50,51). However, the inactive X-chromosome
in the female hiPS and hES cells is maintained in an inactive
state where X-linked genes (i.e. MECP2) retain a monoallelic
expression pattern (38,50,51). To that end, we conﬁrmed the
retention of an inactive X-chromosome in RTT-hiPS cells by
allele-speciﬁc expression analysis of MECP2 (see below).
To investigate the pattern of XCI in D3–4-hiPS cells, we
used the androgen receptor (AR) assay which has been used
previously for investigating XCI patterns in RTT-patient
brains (24). The AR assay detects the heterozygous trinucleo-
tide repeat polymorphism in the ﬁrst exon of the X-linked AR
gene by PCR to distinguish between the paternal and maternal
Figure 3. Female D3–4-hiPS cells retain an inactive X-chromosome. D3–4-hiPS cells were assessed by RNA-FISH and immunocytochemistry for XIST RNA
(A) and H3K27me3 (B), respectively. Graph depicts the percentage of colonies with a single XIST RNA (A) and H3K27me3 (B) signal. Positive (+ve) colonies
indicate that .90% of the cells observed within the colony were positive for the signal. Examples of positive colonies are shown on the left panels. Negative
(2ve) colonies indicate that no cells within the colony were positive for the signal. Mix colonies indicate colonies where a single XIST RNA signal was detect-
able, but were below the threshold for a positive colony. The detection of these XCI marks suggests that D3–4-hiPS cells retain an inactive X-chromosome, at
least in a large fraction of cells. The number of colonies analysed is indicated within each bar. Passage number of analysis is indicated in brackets. P, passage.
Scale bars, 10 mm.
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sensitive enzymes prior to PCR to allow detection of the
(methylated) inactive X-chromosome. The AR assay revealed
that D3–4-ﬁbroblasts exhibited a random pattern of XCI
(69:31) as shown by the detection of two different-sized
amplicons of the AR gene after digestion with methylation-
sensitive enzymes (Fig. 4A, Supplementary Material,
Table S1). On the other hand, all D3–4-hiPS cell lines exhib-
ited an extreme XCI skewing pattern (96:4 to 99:1). Further-
more, D3–4-hiPS #6 and #37 skewed towards the same
parental X-chromosome being inactivated, while D3–4-hiPS
#20 skewed towards the alternative parental X-chromosome
being inactivated. Male BJ-ﬁbroblasts were used as a positive
control for the complete digestion of the (unmethylated)
active X-chromosome resulting in the lack of an AR signal
(Supplementary Material, Fig. S7).
When the AR assay was performed on T158M-hiPS cells, all
T158M-hiPScelllinesshowedanextremeXCIskewingpattern
(91:9 to 99:1) towards the same parental X-chromosome being
inactivated, while T158M-ﬁbroblasts exhibited a random
pattern of XCI (53:47) (Fig. 4B, Supplementary Material,
Table S1). We also performed the AR assay on a previously
Figure 4. XCI is nonrandom in female RTT-hiPS cells. RTT-ﬁbroblasts and -hiPS cells were assessed for XCI patterns via the AR assay. D3–4- (A), T158M-
(B), and R306C- (C) ﬁbroblasts exhibited a random XCI pattern as shown by the presence of two different-sized amplicons, 174 and 180 bp, 168 and 177 bp, and
171 and 174 bp, respectively, after digestion with methylation-sensitive enzymes. D3–4- (A), T158M- (B), and R306C- (C) hiPS cells exhibited an extreme XCI
skewing pattern as shown by the preferential detection of a single-sized peak after digestion with methylation-sensitive enzymes. The corrected XCI ratio (see
Materials and Methods) is indicated on the top left of the digested graph.
2108 Human Molecular Genetics, 2011, Vol. 20, No. 11published RTT-hiPS cell line with the point mutation p.R306C
(30,46), as well as two additional hiPS cell lines from the same
patient. Similar to T158M-hiPS cells, all R306C-hiPS cell lines
showedahighlyskewedpatternofXCI(84:16to81:19)towards
the same parental X-chromosome being inactivated, while
R306C-ﬁbroblasts exhibited a random pattern of XCI (68:32)
(Fig. 4C, Supplementary Material, Table S1). The relatively
lesserdegreeofskewingobservedinR306C-hiPScellsispoten-
tially attributed to the smaller AR amplicon (171 bp) including
the stutter peak of the larger AR amplicon (174 bp) and hence
overestimates the former (see Materials and Methods). The
extreme XCI skewing pattern observed in the RTT-hiPS cells
is similar to previous ﬁndings that female hiPS cells exhibit a
nonrandom XCI pattern (38). Collectively, these data suggest
that RTT-hiPS cells retain an inactive X-chromosome in a
nonrandom pattern. Interestingly, D3–4-hiPS cell lines appear
to have alternative parental X-chromosomes inactivated, but
the T158M- and R306C-hiPS cell lines examined here appear
to have the same parental X-chromosome inactivated.
MECP2 expression follows the pattern of XCI
in RTT-hiPS cells and their neuronal derivatives
The importance of the XCI pattern with respect to RTT is the
expression pattern of the WT or mutant MECP2 in neurons. In
addition, to further assess whether RTT-hiPS cells retain an
Figure 5. MECP2 expression follows the pattern of XCI in RTT-hiPS cells and their neuronal derivatives. RT–PCR (A) and qRT–PCR (B)o fD3–4-hiPS cells
detected WT MECP2 transcripts in D3–4-hiPS #6 and #37 but not in D3–4-hiPS #20, indicating D3–4-hiPS #20 expresses the D3–4 mutant MECP2 transcript.
Diff. fNSCs, differentiated fetal neural stem cells; Fib, ﬁbroblasts. Data are expressed as mean+SEM (B). Sequencing of T158M- (C) and R306C- (D) ﬁbro-
blasts’ cDNA revealed that the ﬁbroblasts express a mixture of WT and mutant MECP2 transcripts as indicated by the ‘C’ and ‘T’ nucleotide peaks, respectively.
Sequencing of T158M- (C) and R306C- (D) hiPS cells revealed that they only express the WT and mutant MECP2 transcripts, respectively. Mut, Mutant. D3–
4-hiPS #20 and #37 were differentiated into neurons for 9–10 weeks. WT MECP2 expression was assessed by immunocytochemistry (E) and qRT–PCR (F) and
was detected in D3–4-hiPS #37-derived neurons but not in D3–4-hiPS #20-derived neurons. Scale bars, 39 mm (E). Diff. fNSCs, differentiated fetal neural stem
cells; Fib, ﬁbroblasts. Data are expressed as mean+SEM (F). (G) D3–4-hiPS #20 and #37 were differentiated into neurons for 9 weeks. D3–4-hiPS #20-derived
neurons exhibited signiﬁcant reduction in soma size compared with D3–4-hiPS #37-derived neurons (∗, P , 0.0001, Student’s t-test). Total number of neurons
(n) analysed per hiPS cell line from two independent biological replicates is indicated at the bottom of each bar. Data are expressed as mean+SEM.
Human Molecular Genetics, 2011, Vol. 20, No. 11 2109inactive X-chromosome despite the loss of XIST RNA and
H3K27me3 in some cells and whether the extreme XCI
skewing pattern represents a nonrandom XCI pattern, we per-
formed allele-speciﬁc expression analysis of MECP2. By
taking advantage of the MECP2 expression in hiPS cells, we
performed reverse transcriptase PCR (RT–PCR) and quanti-
tative (q)RT–PCR in D3–4-hiPS cells using primers that
speciﬁcally detect the WT MECP2 transcript and not the
mutant D3–4 MECP2 transcript. RT–PCR and qRT–PCR
detected the expression of WT MECP2 transcripts exclusively
in D3–4-hiPS #6 and #37 but not in D3–4-hiPS #20,
suggesting that D3–4-hiPS #20 expresses the mutant D3–4
MECP2 transcript (Fig. 5A and B). This is in agreement
with the AR assay data that D3–4-hiPS #6 and #37 have the
same parental X-chromosome inactivated, while D3–4-hiPS
#20 has the alternative parental X-chromosome inactivated.
It is worth noting that when qRT–PCR was performed using
primers upstream of the D3–4 MECP2 mutation (and hence
detect both the WT and mutant D3–4 MECP2 transcripts),
transcripts were detected from D3–4-hiPS #20 (Supplemen-
tary Material, Fig. S8a). This suggests that mutant D3–4
MECP2 transcripts are expressed in D3–4-hiPS #20, at least
upstream of the D3–4 MECP2 mutation.
To determine the pattern of MECP2 expression in T158M-
and R306C-hiPS cells, we performed sequencing of the cDNA
to detect either the expression of the WT nucleotide (C) or the
mutant nucleotide (T) of the p.T158M and p.R306C
mutations, respectively. Sequencing revealed that T158M-
and R306C-ﬁbroblasts have a heterogeneous pattern of XCI
and expressed both the WT and mutant transcripts of
MECP2 consistent with a random XCI status (Fig. 5C and
D). On the other hand, all T158M-hiPS cell lines expressed
the WT MECP2 transcript (Fig. 5C), while all R306C-hiPS
cell lines expressed the mutant MECP2 transcript (Fig. 5D).
This is in agreement with the AR assay that all T158M- and
R306C-hiPS cell lines had the same parental X-chromosome
inactivated. Therefore, the published R306C-hiPS cells do in
fact express the mutant MECP2 transcript, but the
T158M-hiPS cells appear to express the WT MECP2 tran-
script. Collectively, the nonrandom monoallelic expression
pattern of the MECP2 transcript in RTT-hiPS cells demon-
strate that RTT-hiPS cells retain an inactive X-chromosome
in a nonrandom pattern despite the loss of XIST RNA and
H3K27me3 in some cells.
Finally, we sought to determine whether the pattern of WT
and mutant-speciﬁc expression of MECP2 seen in the different
D3–4-hiPS cell lines is maintained upon differentiation. Since
RTT is primarily a neurodevelopmental disorder, we per-
formed directed differentiation of D3–4-hiPS #20 and #37
into the neuronal lineage using previously published protocols
designed for hES cells (52). We chose to focus on D3–4-hiPS
#20 and #37 because they have alternative parental
X-chromosomes inactivated. Furthermore, the nature of the
predicted null mutation (compared with missense mutations
in p.T158M and p.R306C) allows for direct visualization of
the WT MECP2 but not the mutant D3–4 MECP2 at the
protein level via immunocytochemistry using an antibody
raised against the C-terminus of MECP2. D3–4-hiPS cells
were able to differentiate into abundant MAP2-positive
neurons (Fig. 5E). Co-labelling for MECP2 detected WT
MECP2 protein expression exclusively in the nuclei of D3–
4-hiPS #37-derived neurons but not in D3–4-hiPS
#20-derived neurons (Fig. 5E). This was further conﬁrmed
by qRT–PCR as WT MECP2 transcripts were detected exclu-
sively in D3–4-hiPS #37-derived neurons but not in D3–
4-hiPS #20-derived neurons (Fig. 5F). This is in agreement
with the RT–PCR and qRT–PCR results for WT MECP2
transcripts in the D3–4-hiPS cells and suggests that the D3–
4 MECP2 mutation results in the complete absence of the full-
length MECP2 protein and is functionally a null mutation.
Similarly, qRT–PCR using primers upstream of the D3–4
MECP2 mutation detected transcripts from the D3–4-hiPS
#20-derived neurons, suggesting the mutant D3–4 MECP2
transcript is expressed in these neurons, at least upstream of
the D3–4 MECP2 mutation (Supplementary Material,
Fig. S8b). Finally, we performed the AR assay on D3–
4-hiPS #20- and #37-derived neurons and observed an
extreme XCI skewing pattern similar to the parental hiPS
cell lines (Supplementary Material, Fig. S9 and Table S1),
excluding the possibility that XIST RNA- and H3K27me3-
negative D3–4-hiPS cells carry two active X-chromosomes
which would have otherwise resulted in random XCI. From
these data, we conclude that the nonrandom monoallelic
expression of MECP2 in D3–4-hiPS cells is maintained
upon neuronal differentiation and that D3–4-hiPS #37 is an
isogenic control of the mutant D3–4-hiPS #20.
To demonstrate the utility of the isogenic control and
mutant D3–4-hiPS cells, we performed phenotyping of soma
size in D3–4-hiPS cell-derived neurons. We observed that
mutant D3–4-hiPS #20-derived neurons exhibited a signiﬁcant
reduction in soma size compared with isogenic control D3–
4-hiPS #37-derived neurons (Fig. 5G), consistent with pre-
vious ﬁndings in Mecp2
2/y mice and postmortem tissues
from RTT patients (20,53,54). From these data, we conclude
that MECP2 expression is monoallelic in a nonrandom
pattern from a single active X-chromosome in RTT-hiPS
cells and their neuronal derivatives, and that isogenic D3–
4-hiPS cell lines have been generated that express either the
WT or mutant MECP2 after directed differentiation into neur-
onal lineages. Finally, we provide a proof-of-principle exper-
iment to demonstrate the utility of the isogenic D3–4-hiPS
cell-derived neurons for elucidating the pathogenesis of RTT
in vitro.
DISCUSSION
In this study, we established isogenic RTT-hiPS cell lines that
express either the WT or mutant allele of MECP2. We mapped
a functionally null mutation in MECP2 for a classic RTT
patient that consisted of a pair of deletions, one of which is
also associated with an insertion, that removes exon 3 and
the 5′ end of exon 4. This mutation ultimately removes the
entire MBD and TRD from the MECP2 coding region. The
pair of deletions seem to be caused by two different mechan-
isms with the larger deletion potentially caused by Alu
recombination-mediated deletions and is associated with an
insertion, while the smaller deletion is potentially caused by
microhomology-mediated processes (42–45). We established
D3–4-hiPS cell lines from this patient and from ﬁbroblasts
2110 Human Molecular Genetics, 2011, Vol. 20, No. 11carrying another RTT-associated p.T158M point mutation in
MECP2. D3–4- and T158M-hiPS cells were shown to be plur-
ipotent and fully reprogrammed. Consistent with recent ﬁnd-
ings (38), female RTT-hiPS cells retain an inactive
X-chromosome as suggested by the expression of a single
XIST RNA and H3K27me3 signal in the RTT-hiPS cell colo-
nies. Furthermore, the pattern of XCI is nonrandom as
suggested by the extreme XCI skewing pattern detected by
the AR assay. Most interestingly, we obtained D3–4-hiPS
cell lines that have alternative parental X-chromosomes inac-
tivated with D3–4-hiPS cell lines #6 and #37 inactivating one
of the parental X-chromosomes, while D3–4-hiPS #20 inacti-
vated the alternative parental X-chromosome. This XCI
pattern raised the prospect of isolating a pair of isogenic
control and experimental D3–4-hiPS cell lines. Indeed, D3–
4-hiPS #6 and #37, but not D3–4-hiPS #20, speciﬁcally
expressed WT MECP2 transcripts. Furthermore, when
directed differentiation was performed towards the neuronal
lineage on D3–4-hiPS #20 and #37, the primary cell type
affected in RTT (20), WT MECP2 transcripts and protein
were detected only in neuronal derivates of D3–4-hiPS #37
but not of D3–4-hiPS #20. This indicates that the D3–4
MECP2 mutation results in the complete absence of the full-
length MECP2 protein and is functionally a null mutation.
From these data, we conclude that D3–4-hiPS #37 is an iso-
genic control for the mutant D3–4-hiPS #20.
In contrast to D3–4-hiPS cells, we were not able to isolate
T158M- and R306C-hiPS cell lines that had alternative par-
ental X-chromosomes inactivated. This is unlikely to be due
to differences in reprogramming efﬁciencies of ﬁbroblasts
expressing WT or mutant MECP2, as both alleles of MECP2
expression were obtained, where all the T158M-hiPS cell
lines expressed the WT MECP2 transcript while all
R306C-hiPS cell lines expressed the mutant MECP2 tran-
script. It is also unlikely to be due to a skewed XCI pattern
in the parental ﬁbroblasts, as they had a random XCI pattern
and expressed both the WT and mutant MECP2 transcripts.
Therefore, we propose that the distribution of MECP2 allele
expression in T158M- and R306C-hiPS cell lines was due to
chance, and it is crucial to screen a larger cohort of hiPS
cell lines for heterozygous X-linked disorders compared with
autosomal disorders to ensure the generation of isogenic
control and experimental hiPS cell lines. We recommend
screening for hiPS cell lines carrying alternative parental
X-chromosomes inactivated using the AR assay followed by
conﬁrmation of the WT or mutant RNA or protein expression
directly in hiPS cells or the differentiated cell type of interest
prior to performing extensive pluripotency characterization.
While our work was being completed, Muotri and col-
leagues (55) published elegant work demonstrating the
utility of RTT-hiPS cells for understanding RTT. Interestingly,
however, and distinct from our present study, their described
RTT-hiPS cells possessed two active X-chromosomes with a
random pattern of XCI upon differentiation into neuronal
derivatives and hence their phenotyping relied on comparisons
to control hiPS cells generated from unrelated healthy
individuals. The generation of female RTT-hiPS cells retain-
ing an inactive X-chromosome with a nonrandom XCI
pattern in the present study is consistent with the female
hiPS cells described by Plath and colleagues (38), but not
with the female RTT-hiPS cells described by Muotri and col-
leagues (55). This discrepancy may be attributed to differences
in reprogramming methods and culturing of hiPS cells which
remain to be determined.
The generation of isogenic RTT-hiPS cell lines is advan-
tageous for several reasons. For disease phenotyping, appro-
priate healthy control hiPS cells are essential and isogenic
cells from the same patient eliminate the diversity of genetic
backgrounds that exist between individuals. Previous studies
of disease phenotyping in patient-speciﬁc hiPS cells have
used unaffected parents (32), unrelated healthy individuals
(33–37,55) and hES cells (33) as controls. Although these
studies report disease-associated phenotypes in affected hiPS
cells, confounding effects due to differences in genetic back-
ground and modiﬁer genes cannot be entirely excluded. Fur-
thermore, isogenic D3–4-hiPS cell lines may respond to
directed differentiation cues in a more uniform manner com-
pared with hiPS and hES cell lines generated from different
individuals (56,57). For these reasons, we hypothesize that
future downstream applications with D3–4-hiPS cell lines
will be able to identify phenotypes that are speciﬁc to the
MECP2 mutation. Finally, it would be of interest to mix the
mutant and isogenic control D3–4-hiPS cells in different rela-
tive proportions prior to neuronal differentiation to recapitu-
late the mosaic mutant and WT MECP2 expression pattern
that exists in RTT girls for downstream applications.
The D3–4 MECP2 mutation mapped in this study presents
several advantages over the common missense and nonsense
point mutations for studying RTT in vitro (11). The complete
absence of the full-length MECP2 protein with the two func-
tional domains, MBD and TRD, in this mutation will likely
lead to more pronounced phenotypes for downstream appli-
cations compared with hypomorphic missense p.T158M and
p.R306C alleles and nonsense Mecp2
308 alleles that retain
partial function (21,40,41). Indeed, it has been reported that
RTT patients with large deletions in MECP2 present with a
higher severity score than non-deleted patients (13). The
D3–4 MECP2 mutation is also more amenable to rescue
experiments using transgenes as there is no residual functional
full-length MECP2. In contrast, rescue of the p.T158M and
p.R306C point mutations will require targeted correction of
the expressing allele, or transgenes that simultaneously knock-
down the hypomorphic mutant MECP2 and express WT
MECP2 at normal levels.
Finally, the generation of D3–4-hiPS derived-neurons
allow the study of MECP2 function in human neurons and
for disease phenotyping which has traditionally been difﬁcult
due to lack of human brain tissues from RTT patients for
research purposes. To this end, we provide proof-of-principle
evidence to demonstrate the utility of the isogenic RTT-hiPS
cells as mutant D3–4-hiPS #20-derived neurons exhibited a
signiﬁcant reduction in soma size compared with isogenic
control D3–4-hiPS #37-derived neurons, consistent with pre-
vious ﬁndings suggesting neuronal maturation is affected in
RTT (20,53,54). With the identiﬁcation of RTT-associated
phenotypes in D3–4-hiPS cell-derived neurons, it may be
possible to use these neurons for drug screens. This is of
particular interest as drug targets will act on pathways that
compensate for the complete loss of functional MECP2 in
the D3–4 MECP2 mutant. This is in contrast to p.T158M
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increasing the hypomorphic MECP2 function or reversing
the effect of speciﬁc mutations, such as conformation
changes of the protein.
In conclusion, to the best of our knowledge, this is the ﬁrst
report where a large complex genetic mutation has been
mapped, patient ﬁbroblasts successfully reprogrammed and a
disease-speciﬁc phenotype observed in cell types differentiated
fromexperimentalhiPScelllinescomparedwiththosefromiso-
genic control hiPS cell lines generated from the same patient.
We conﬁrm recent ﬁndings that female hiPS cells retain an
inactive X-chromosome in a nonrandom XCI pattern and can
be exploited to generate isogenic control and experimental
hiPS cells from heterozygous X-linked diseases (38). The iso-
genic D3–4-hiPS cells reported in the present study will have
important implications for determining the pathogenesis of
RTT and the role of MECP2 in human neurons.
MATERIALS AND METHODS
MECP2 genotyping
To map the D3–4MECP2 mutation, the region of the deletion
was ﬁrst determined via qPCR using primers (Supplementary
Material, Table S2), some of which were previously described
(12), spanning the MECP2 locus to determine copy number
variations. Genomic DNA was isolated using phenol/chloro-
form extraction. qPCR was performed with 50 ng of DNA
using SYBR Green PCR Master Mix on a 7900 HT Fast
Real Time PCR System (all from Applied Biosystems) as
per manufacturer’s instructions. All reactions were done in tri-
plicates with the average used for subsequent analysis. Stan-
dard curves were generated for each primer set and product
speciﬁcity was assessed using melting curve analysis. The
MECP2 amplicon of interest and the FOXP2 reference ampli-
con (Supplementary Material, Table S2) were ampliﬁed for
the D3–4-ﬁbroblasts and -hiPS cells, normal male BJ-ﬁbro-
blasts were used as a reference for one copy and normal
female IMR90-ﬁbroblasts were used as a positive control for
two copies. The copy number of MECP2 was normalized to
that of FOXP2 to normalize for differences in DNA input.
The delta–delta Ct method was used to determine copy
number. The data are expressed as mean+standard error of
the mean (SEM). To map the precise breakpoints of the
D3–4MECP2 mutation, the WT MECP2 allele was ampliﬁed
using KR6-Fwd and KR16-Rev primers, and the D3–4
MECP2 allele was ampliﬁed using AC7-Fwd and KR16-Rev
primers (Supplementary Material, Table S2). The D3–4
MECP2 mutant amplicon was gel puriﬁed using NucleoSpin
Extract II (Macherey-Nagel) as per manufacturer’s instruc-
tions and sequenced [The Centre for Applied Genomics
(TCAG), The Hospital for Sick Children, Canada] using the
same primers for ampliﬁcation. Breakpoints and insertions
were determined by aligning with the MECP2 genomic
DNA sequence (NCBI Reference Sequence: NG_007107.1).
AluSx elements were found using RepeatMasker Open-3.0
(http://www.repeatmasker.org). The precise position of the
g.67072_67200del was determined by identifying the 3 bp
homology upstream of the breakpoint as the breakpoint
occurs 3′ to the microhomology (45). Sequencing of the
p.T158M mutation was performed by amplifying DNA with
RTT primers (Supplementary Material, Table S2). The ampli-
con was gel puriﬁed and sequenced using the same primers for
ampliﬁcation.
Cell culture
D3–4-ﬁbroblasts were generated and expanded from a skin
punch biopsy of a classic RTT patient at The Hospital for Sick
Children, Canada, under the approval of the SickKids Research
Ethics Board. T158M (GM17880)- and R306C (GM11270)-
ﬁbroblasts were acquired from the Coriell Cell Repository.
Human male BJ-ﬁbroblasts (CRL-2522) and female IMR90-
ﬁbroblasts (CCL-186) were obtained from American Type
Culture Collection (ATCC). Fibroblasts from Coriell and
ATCC were maintained in Dulbecco’s modiﬁed Eagle
medium and minimum Essential medium, respectively, sup-
plemented with 10% fetal bovine serum and penicillin/strepto-
mycin (100×) (all from Invitrogen). hiPS cell generation from
ﬁbroblasts and culture was performed as previously described
(30,46). CA1 and H9 hES cells were obtained from A. Nagy
(Mount Sinai Hospital, Toronto, Canada) and The WiCell
ResearchInstitute(Wisconsin,USA),respectively,andcultured
undertheapprovaloftheCanadianInstitutesofHealthResearch
Stem Cell Oversight Committee. Culture conditions for hES
cells are identical to those for hiPS cells (30,46).
Immunocytochemistry
Cells were rinsed with 2× phosphate-buffered saline (1×)
(PBS) (Invitrogen) washes, ﬁxed with 4% formaldehyde
(EMD Biosciences) diluted in PBS for 10 min at room temp-
erature (RT), rinsed with 3× PBS washes for 5 min at RT,
permeabilized with 0.1% Nonidet P-40 (Sigma) diluted in
PBS for 10 min at RT and rinsed with 3× PBST [PBS +
0.1% Tween-20 (Sigma)] washes for 10 min at RT. Cells
were blocked in 10% serum of host species [Normal Goat
Serum (Cedarlane), Normal Donkey Serum (Millipore)] of
secondary antibody and 1% bovine serum albumin (Sigma)
diluted in PBST (block solution) overnight at 48C. Cells
were then incubated with primary antibodies (Supplementary
Material, Table S3) diluted in block solution overnight at
48C. Cells were rinsed with 3× PBST washes for 10 min at
RT and incubated with appropriate Alexa Fluor secondary
antibodies (Invitrogen) diluted (1:500) in block solution
for 1 h at RT, followed by 3× PBST washes for 10 min at
RT. Nuclei were stained with 0.5 mgm l
21 4′,6-diamidino-2-
phenylindole dihydrochloride (DAPI) (Sigma) diluted in
PBS for 10 min at RT followed by 2× PBS washes.
Neurons grown on cover slips (Bellco) were processed in an
identical manner except that it was mounted on slides with
0.5 mgm l
21 DAPI diluted in ﬂuorescent mounting medium
(Dako). Images were captured using a Leica DMI4000B
microscope equipped with Leica DFC340FX camera and
Leica Application Suite software or Zeiss Axiovert 200M
microscope equipped with a Hamamatsu C9100-13 EMCCD
camera and Improvision Volocity software. Soma size analysis
of neurons was performed using Improvision Volocity soft-
ware on 40× images from 50 randomly selected ﬁelds from
26 cover slips over two independent biological replicates of
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RNA isolation and PCR analysis
Total RNA was isolated using TRIzol Reagent (Invitrogen) as
per manufacturer’s instructions. Complementary DNA
(cDNA) was generated from 1 mg of DNase I (Invitrogen)-
treated total RNA using SuperScript II (Invitrogen) as per
manufacturer’s instructions. RT–PCR and qRT–PCR were
performed using speciﬁc primer sequences (Supplementary
Material, Table S2). qRT–PCR was performed as described
for qPCR in MECP2 genotyping. The housekeeping gene,
ACTB (BETA-ACTIN), was used to normalize for differences
in cDNA input. For exogenous reprogramming factors,
IMR90-ﬁbroblasts freshly infected with OCT4, SOX2, KLF4,
c-MYC and mRFP1 retroviral vectors (IMR90-4F + RFP)
were used as a positive control; for endogenous pluripotency
loci, H9 hES cells were used as a positive control. Sequencing
of p.T158M and p.R306C from cDNA was performed by
amplifying cDNA with MBD-Fwd and MECP2 Ex4-Rev
primers or MECP2 Ex4-Fwd and RTT-Rev primers, respect-
ively (Supplementary Material, Table S2). Amplicons were
puriﬁed using a QIAquick PCR Puriﬁcation Kit (Qiagen) as
per manufacturer’s instructions and sequenced using the
same primers for ampliﬁcation. Differentiated fetal neural
stem cells which differentiate into 10–20% neurons
(astrocytes make up the remaining percentage) were used
as a positive control for RT–PCR and qRT–PCR for
MECP2 (kind gift from P. Dirks). RT–PCR and qRT–PCR
for WT MECP2 were performed using WT MECP2 and
MECP2 Ex4 primers, respectively (Supplementary Material,
Table S2). fetal neural stem cells (fNSCs) were isolated
from tissues obtained under the approval of the SickKids
Research Ethics Board.
In vitro and in vivo differentiation
For in vitro differentiation, hiPS cells were detached (Col-
lagenase IV, Invitrogen) and grown in suspension on low
attachment surfaces (Corning) in hiPS cell medium (30,46)
without basic ﬁbroblast growth factor for 8 days to form
embryoid bodies with medium changes every other day.
Embryoid bodies were adhered on to plastic surfaces and
allowed to further differentiate for 8 days with medium
changes every other day. Cells were then analysed via
immunocytochemistry for markers representative of the three
germ layers (Supplementary Material, Table S3). For in vivo
differentiation, one 10 cm dish of hiPS cells were detached
and resuspended in a mixture of Knockout DMEM (Invitro-
gen), Matrigel (BD Biosciences), Collagen (STEMCELL
Technologies) (ratio 2:1:2) and 10 mM ROCK Inhibitor
(Sigma) and injected intramuscularly into immunodeﬁcient
mice. Tumours were harvested 9–12 weeks after injection.
Fixed tumours were embedded in parafﬁn, sectioned and
stained with haematoxylin and eosin for pathological analysis.
hES cells and mouse embryonic ﬁbroblasts were used as posi-
tive and negative controls, respectively (data not shown). All
procedures using animals were approved by the SickKids
Animal Care Committee under the auspices of The Canadian
Council on Animal Care, and conducted with the approval
of the Canadian Institutes of Health Research Stem Cell Over-
sight Committee.
Karyotyping and DNA ﬁngerprinting
Standard G-banding chromosome analysis with a 400–500
banding resolution was performed at TCAG. DNA ﬁngerprint-
ing was performed using the GenomeLab Human STR Primer
Set and analysed by the GenomeLab GeXP Genetic Analysis
System (all from Beckman Coulter) as per manufacturer’s
instructions.
RNA-FISH and DNA-FISH
XIST RNA-FISH and/or X-centromere DNA-FISH was per-
formed using probes and protocols as previously described
(58,59). Probes were directly labelled using Nick Translation
and Ares Alexa Fluor DNA labelling kits (Invitrogen).
Slides were viewed on Nikon TE2000-U microscope with a
Roper Scientiﬁc CCD camera and NIS elements software
package. At least 12 colonies were scored for each line.
Results within a colony are based on scoring cells from
three independent ﬁelds of vision at 60× magniﬁcation
(.75 cells scored per colony). XIST RNA-positive colonies
had a large accumulation of XIST RNA in .90% of the
cells in each observed region. Colonies that were scored as
XIST RNA-negative had no observable XIST RNA. Occasion-
ally, colonies exhibit a mixture of XIST RNA-positive and
-negative cells. For DNA-FISH, the same criteria were used
to classify colonies as diploid or aneuploid for the X chromo-
some.
AR assay
To analyse XCI patterns, 200 ng of DNA was digested for 2 h
at 378C with methylation-sensitive enzymes HpaII and HhaI
(Invitrogen) simultaneously to obtain the (methylated) inactive
X-chromosome only. To differentiate between the two par-
ental X-chromosomes, 20 ng of digested and undigested
DNA was ampliﬁed with primers (Supplementary Material,
Table S2) designed against the polymorphic trinucleotide
(CAG) repeat in the ﬁrst exon of the AR gene for 32 cycles.
The 5′ end of the forward primer is labelled with FAM ﬂuor-
escein (Invitrogen). PCR products were analysed at TCAG. In
brief, PCR products were separated on an ABI3100 Genetic
Analyzer with 500 LIZ size standard and analysed by Peak
Scanner software (all from Applied Biosystems). The XCI
ratio was calculated as previously described (55). In brief, a
correction factor was calculated using peak areas of the undi-
gested samples to normalize for preferential ampliﬁcation of
one of the two AR alleles. The XCI ratio was then calculated
using the corrected peak area in the digested samples. Male
BJ-ﬁbroblasts were used as a positive control for complete
digestion of the (unmethylated) active X-chromosome. For
R306C-ﬁbroblasts and -hiPS cells, the 171 bp allele will
include the stutter peak of the 174 bp allele. Therefore, the
signal of the 171 bp allele will be an overestimate. Stutter
peak is deﬁned as a 3 bp smaller peak due to polymerase slip-
page over trinucleotide repeat sequences.
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Neuronaldifferentiationwasperformedaspreviouslydescribed
withslightmodiﬁcations(52).Inbrief,hiPScellsweredetached
and resuspended in hiPS cell medium (30,46) without basic
ﬁbroblast growth factor for 3 days with medium changes
every day. Cellular aggregates were then cultured for 3 days
in neuronal medium, with medium changes every other day,
consisting of Dulbecco’s modiﬁed Eagle medium: nutrient
mixture F-12 (1×), N2 (100×), MEM non-essential amino
acids (100×) (all from Invitrogen), and 2 mgm l
21 heparin
(Sigma). Suspended cellular aggregates were then adhered on
to a plastic surface coated with 20 mgm l
21 laminin (Roche)
for 11 days in neuronal medium to generate neuroepithelial
cells with medium changes every other day. Neuroepithelial
cells were manually detached and cultured as neuroepithelial
clusters for 4 days in neuronal medium with medium changes
every other day. For neuronal differentiation, neuroepithelial
clusters were adhered on to 0.1 mg ml
21 poly-L-ornithine
(Sigma) and20 mgm l
21laminin-coated cover slipsinneuronal
differentiation medium consisting of neurobasal, N2 (100×),
MEM non-essential amino acid (100×), B27 without vitamin
A (50×), penicillin/streptomycin (100×) (all from Invitrogen),
brain-derived neurotrophic factor, glial cell line-derived
neurotrophic factor, insulin-like growth factor-1 (all from
Peprotech at 10 ng ml
21), 1 mM N6,2′-O-dibutyryladenosine
3′,5′-cyclic monophosphate sodium salt, 200 ng ml
21 ascorbic
acid (all from Sigma), and 1 mgm l
21 laminin. Neuronal differ-
entiation medium was changed every other day as neurons
differentiate from the neuroepithelial clusters and mature over
the next seven weeks (52,60).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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